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Background: There is persistent confusion as to whether abacavir
(ABC) increases the risk of myocardial infarction (MI), and whether
such risk differs by type 1 (T1MI) or 2 (T2MI) MI in adults
with HIV.
Methods: Incident MIs in North American Cohort Collaboration
on Research and Design participants were identified from 2001 to
2013. Discrete time marginal structural models addressed channeling
biases and time-dependent confounding to estimate crude hazard
ratio (HR) and adjusted hazard ratio (aHR) and 95% confidence
intervals; analyses were performed for T1MI and T2MI separately. A
sensitivity analysis evaluated whether Framingham risk score (FRS)
modified the effect of ABC on MI occurrence.
Results: Eight thousand two hundred sixty-five adults who initiated
antiretroviral therapy contributed 29,077 person-years and 123 MI
events (65 T1MI and 58 T2MI). Median follow-up time was 2.9
(interquartile range 1.4–5.1) years. ABC initiators were more likely
to have a history of injection drug use, hepatitis C virus infection,
hypertension, diabetes, impaired kidney function, hyperlipidemia,
low (,200 cells/mm3) CD4 counts, and a history of AIDS. The risk
of the combined MI outcome was greater for persons who used ABC
in the previous 6 months [aHR = 1.84 (1.17–2.91)]; and persisted for
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T1MI (aHR = 1.62 [1.01]) and T2MI [aHR = 2.11 (1.08–4.29)]. FRS
did not modify the effect of ABC on MI (P = 0.14) and inclusion of
FRS in the MSM did not diminish the effect of recent ABC use on
the combined outcome.
Conclusions: Recent ABC use was associated with MI after
adjustment for known risk factors and for FRS. However, screening
for T1MI risks may not identify all or even most persons at risk of
ABC use-associated MIs.
Key Words: HIV, abacavir, myocardial infarction, causal inference
(J Acquir Immune Defic Syndr 2018;78:62–72)
INTRODUCTION
Aging adults with HIV are at increased risk of
myocardial infarction (MI) compared with otherwise similar
adults without HIV.1,2 This increased risk is likely the result
of an amalgam of simultaneously occurring factors, includ-
ing: (1) increased prevalence of traditional MI risk factors
among adults with HIV3–6; (2) HIV-associated immune
activation and dysregulation, excess inflammation, and hyper-
coagulation7,8 that is blunted but not normalized with
antiretroviral (ART)-induced virologic suppression and7,9,10;
(3) possibly the use of specific ART drugs.4,11,12
lated GFR , 60 mL/min). Because renal insufficiency is an
independent risk of MI, selection of ABC for use among
persons with kidney disease may represent a channeling bias
enriching the population of ABC users with persons who
have higher MI risk compared with nonusers; such bias may
have influenced ABC use from 2008 onward13,21,22 in
individuals with known CVD risk factors. Furthermore, given
the links between protease inhibitor (PI) use and dyslipidemia
(which may increase the risk of MI), as well as the link
between delayed ART therapy initiation and low CD4 counts
(which have also been linked with MIs),23 time-dependent
confounding of the ABC and MI relationship is possible.
The objective of the current analysis was to determine
the effect of recent ABC use on the risk of MIs overall and
stratified as either a type1 MI (T1MI) or type 2 MI (T2MI).
We used data from the North American Cohort Collaboration
on Research and Design (NA-ACCORD) and analytical
methods that attempted to account for potential channeling
bias and time-dependent confounding of the ABC and
MI relationship.
METHODS
Study Population: The NA-ACCORD
The NA-ACCORD is the largest consortium of HIV
cohorts in the United States and Canada. It serves as the North
American region of the International Epidemiology Databases
to Evaluate AIDS project, supported by the National Institutes
of Health. Details on this collaboration have been published
previously.24 Briefly, NA-ACCORD consists of single and
multisite clinical and interval cohort studies that accumulate
data from adults ($18 years old) with HIV at $200 sites in
the United States and Canada. Participating cohorts submit
comprehensive data on enrolled participants to the Data
Management Core (University of Washington, Seattle,
WA), where data are harmonized across cohorts and trans-
mitted to the Epidemiology/Biostatistics Core (Johns Hopkins
University, Baltimore, MD), which conducted the analyses
presented here. The human subject research activities of the
NA-ACCORD and each of the participating cohort studies
have been reviewed and approved by their respective local
institutional review boards and by the Johns Hopkins
University School of Medicine.
For this study, 7 US clinical cohorts within the NA-
ACCORD with complete access to both inpatient and outpatient
electronic medical records validated the occurrence of MI
between January 1, 2001, and December 31, 2013. The study
population was restricted to persons observed to initiate ART. A
flowchart depicting the selection of NA-ACCORD participants
for the current study can be found in Supplemental Digital
Content Figure 1, http://links.lww.com/QAI/B120.
Outcome: MI
The primary outcome for this study was incident MI.
The protocol for ascertainment, validation, and classification
of MIs within the NA-ACCORD has been previously
published.25 Briefly, potential MI events were centrally
There have been conflicting reports linking increased 
risks of MI and use of nucleoside reverse transcriptase 
inhibitor agents, with considerable attention focused on 
abacavir (ABC). Initial reports came from the Data Collection 
on Adverse Events of Anti-HIV Drugs (D:A:D cohort); D:A: 
D remains the largest cohort in which this relationship has 
been examined systematically to date. Their analysis included 
25,000 adults with HIV followed prospectively for at least 10 
years and demonstrated a nearly 2-fold risk of MI incidence 
associated with recent ABC exposure (with the previous 6 
months), although more remote or cumulative ABC expo-
sures were not associated.13
Other observational studies have corroborated these 
findings.14–17 The French Hospital Database on HIV18 
initially reported findings similar to those of D:A:D regarding 
recent ABC use and MI risk (odds ratio = 2.01, 95%
confidence interval: 1.11 to 3.64) but this association did 
not remain significant after accounting for cocaine or 
intravenous drug use.18
Other cohorts have failed to identify such an associa-
tion19 The U.S. Food and Drug Administration undertook 
a meta-analysis, including participants in randomized con-
trolled trials, and found no increased risk of cardiovascular 
disease (CVD) associated with ABC use.20 However, of the 
26 studies included in this analysis, only 5 reported a mean 
follow-up time .2 years and none reported a follow-up time 
of .5 years.20 Reports from cohorts that have not demon-
strated an ABC/MI association have differed widely in 
analytic methodology and clinical definitions used.
Tenofovir disoproxil fumarate (TDF) has been used 
more commonly in combination ART regimens than ABC 
since both became available, and ABC use has been more 
common among persons for whom TDF use was contra-
indicated, particularly because of renal impairment (calcu-





ABC (n = 6803)
N % N %
Age (yrs)
,40 545 37 3174 47
40–49 556 38 2293 34
50–59 294 20 1095 16
60–69 67 5 241 4
Male 1083 74 5519 81
Race and ethnicity
White 570 39 3135 46
Black 673 46 2289 34
Hispanic 130 9 889 13
Other/unknown 89 6 490 7
HIV transmission risk
MSM 635 43 3920 58
IDU 251 17 628 9
Heterosexual 465 32 1769 26
Other 111 8 486 7
Year of ART initiation
2001–2004 651 45 1105 16
2005–2007 399 27 1728 25
2008–2013 412 28 3870 58
Ever cigarette smoker 1083 74 4995 73
Hepatitis C infection 364 25 1047 15
Treated hypertension 422 29 1166 17
Diabetes mellitus 107 7 288 4
Renal function (eGFR $60) 1328 91 6691 98
High LDL ($130 mg/dL) 270 18 1278 19
Low HDL (#40 mg/dL men,
(#50 mg/dL women
699 48 3739 55
High total cholesterol ($240 mg/dL) 202 14 668 10
Total cholesterol: HDL ratio $5.0 425 29 2207 32
High triglycerides ($300 mg/dL) 488 33 1975 29
Statin use 108 7 364 5
CD4 count (cells/mm3)
$350 348 24 2207 32
200–349 476 33 2204 32
,200 638 44 2392 35
Detectable HIV viral load
(.400 copies/mL)
1294 89 6133 90
History of clinical AIDS diagnosis 433 30 1358 20
HIV treatment regimen
Non-PI ART 788 54 4034 59









MI Outcomes 36 5333 87 23,745
T1MI
outcomes
17 5268 48 23,650
T2MI
outcomes
19 5263 39 23,615
Hepatitis C infection was defined as (1) a positive antibody test, or (2) a detectable
HCV RNA, or (3) the presence of a genotype result. If an individual ever met this
definition, they were considered HCV-infected at all times under observation (a time-
fixed variable).
Hypertension was defined as (1) a hypertension diagnosis, and (2) prescription for
an antihypertensive medication.
Diabetes was defined as (1) a diabetes diagnosis and prescription for diabetes-
related medications, or (2) prescription for a diabetes-specific medication, or (3)
hemoglobin A1C $6.5%.
Renal function was estimated as eGFR calculated using the Chronic Kidney Disease
Epidemiology Collaboration study equation.
The “study entry” window used for measurement of hypertension, diabetes, and
renal function was as close to study entry as possible, within the window of before study
entry through 9 months after study entry.
High low-density lipoprotein (LDL) was defined as LDL $130 mg/dL. If there was
an LDL measurement $130 mg/dL within the window of before study entry through 9
months after study entry, then the individual was classified as having high LDL for the
entire time they were under observation; otherwise, they were classified as having LDL
,130 mg/dL.
Low high-density lipoprotein (HDL) was defined as #40 mg/dL for men and #50
mg/dL for women. If there was an HDL measure#40 mg/dL for men or #50 mg/dL for
women within the window of before study entry through 9 months after study entry, then
the individual was classified as having low HDL for the entire time they were under
observation; otherwise, they were classified as having HDL .40 mg/dL.
High total cholesterol was defined as total cholesterol $240 mg/dL. If there was
a total cholesterol measurement $240 mg/dL within the window of before study entry
through 9 months after study entry, then the individual was classified as having high
cholesterol for the entire time they were under observation; otherwise, they were
classified as having total cholesterol ,240 mg/dL.
High triglycerides was defined as triglycerides $300 mg/dL. If there was
a triglyceride measure $ 300 mg/dL within the window of before study entry through
9 months after study entry, then the individual was classified as having high triglycerides
for the entire time they were under observation; otherwise, they were classified as having
triglycerides ,300 mg/dL.
Statin use included prescription of cerivastatin, fluvastatin, lovastatin, pravastatin,
rosuvastatin, simvastatin, pravastatin & aspirin, atorvastatin & amlodipine, ezetimibe &
simvastatin, pitavastatin, lovastatin & niacin. Statin prescription was measured within
the window of before study entry through 9 months after study entry.
CD4 count and HIV RNA were measured at measured as close to study entry as
possible, within the window of 9 months before study entry through 3 months after
study entry.
History of clinical AIDS diagnosis was defined as those who had a first clinical
AIDS diagnosis at, or before, study entry.
HIV treatment regimen used was measured as close to study entry as possible,
within the window of 6 months before study entry through study entry.
Age, sex, race/ethnicity, and HIV transmission risk group were measured at 
enrollment into the NA-ACCORD. Cigarette smoking status was determined as ever 
having medical record information or substance survey information that denoted 
cigarette smoking.
ascertained within the NA-ACCORD data repository using 
a standard protocol based on primary screening for MI that 
included the presence of an inpatient or outpatient MI 
diagnosis (International Classification of Diseases, Ninth 
Revision, Clinical Modification [ICD-9] diagnoses including 
410 codes, 411.0, 412, and 429.7), or serum cardiac enzyme 
levels above the laboratory-specific upper limit of normal for 
troponin-I, troponin-T, or creatine kinase MB. Comprehen-
sive medical records regarding each potential MI identified by 
this screening were abstracted from electronic medical 
records, deidentified, and uploaded to the central NA-
ACCORD data repository using a secure website. Information 
regarding specific ART drug use was redacted to avoid 
possible reviewer bias. Each potential MI event was adjudi-
cated by at least 2 physician reviewers with extensive 
expertise in MI adjudication. A third review was conducted 
if discrepancies occurred. Events were classified as either 
T1MI, which is caused by atherosclerotic plaque rupture or 
erosion with intraluminal thrombus, or T2MI, which is caused 
by ischemic imbalance between myocardial oxygen supply 
and demand often found in the settings of hypotension and 
sepsis according to the universal definition of MI.26 Re-
viewers also identified persons who screened positive for an
of an HMG-CoA reductase inhibitor medication. Low high-
density lipoprotein cholesterol was defined as #40 mg/dL for
men and #50 mg/dL for women. High low-density lipopro-
tein was defined as $130 mg/dL. Elevated total cholesterol
was defined as $240 mg/dL. These were considered
dichotomous variables. Because of the effect of statins, only
low-density lipoprotein and total cholesterol measurements
before statin initiation were considered. Elevated triglycerides
were defined as $300 mg/dL. We calculated estimated
glomerular filtration rate (eGFR) using the Chronic Kidney
Disease Epidemiology Collaboration equation and27 dichot-
omized eGFR to represent renal function (eGFR $60 and
,60 mL/min).
History of an AIDS-defining illness was based on clinical
diagnoses defined according to the 1993 CDC case definition28;
a CD4 count ,200 cells/mL was not included in this definition.
CD4 cell count was categorized in 3 strata (,200, 200–349, and
$350 cells/mL). HIV virologic suppression was defined as
a plasma HIV-1 RNA level#400 copies per milliliter. ART was
defined as 3 ARV agents from at least 2 classes or a triple
nucleoside reverse transcriptase inhibitor regimen containing
ABC or TDF. Because of previous studies29 suggesting a link
between use of ART combinations that included a protease
inhibitor (PI-based) with MI,29,30 HIV treatment regimens were
classified as PI-based and non–PI-based.
Statistical Analysis
We used marginal structural models (MSMs)30 to
determine the risk of MI with ABC use as a time-varying
exposure in the presence of time-varying confounders that
are affected by previous treatment. This approach accounts
for channeling bias that may have existed among individ-
uals with renal function impairment (and potentially higher
FIGURE 1. Kaplan–Meier survival estimates for time from ART initiation to first MI, by recent (within the last 6 months) ABC use,
NA-ACCORD. Numbers above the x-axis denote the number of participants at risk at 1, 4, and 8 years after ART initiation (top: no
ABC; bottom: recent ABC use). MI, T1MI and T2MI; primary, T1MI; secondary, T2MI.
MI and then underwent a cardiac intervention indicating 
severe underlying coronary artery disease (usually coronary 
artery bypass graft or percutaneous coronary intervention 
with stent placement); these events were considered validated 
MIs and classified as T1MIs.
For this study, only incident MI events were included as 
an outcome. A patient with an MI identified at or before ART 
exposure (baseline) was excluded from subsequent analysis.
Exposure: Recent ABC Use
Exposure to ABC was measured from prescription and 
medical records. Recent ABC use was updated as a time-
varying variable in the analysis and defined as any reported 
use within the previous 6 months.
Confounders
Sex, race and ethnicity, year of birth, and HIV trans-
mission risk [including injection drug use (IDU)] were self-
reported at enrollment. Cigarette smoking was defined as ever 
having smoked cigarettes based on clinician-recorded diag-
noses and/or patient-reported responses to questionnaires 
administered by individual cohorts. Hepatitis C virus 
(HCV) infection was defined as having a positive serum 
HCV antibody test, detectable plasma HCV RNA, or 
evidence of an HCV genotype test as reported in medical 
records while under observation in the NA-ACCORD.
Treated hypertension was defined as a clinical diagnosis 
of hypertension and a prescription of antihypertensive 
medication. Diabetes mellitus was defined as a diagnosis of 
diabetes and prescription of diabetes-related medication, or 
a diabetes-specific medication, or a glycosylated hemoglobin 
(HbA1c) level $6.5%. Statin use was defined as prescription
TABLE 2. Estimated Crude HR and aHR and 95% Confidence Intervals (95% CI) from Marginal Structural Models for the Risk of
MI After ART Initiation, Overall and by MI Type, N = 8265 and n = 123 MIs (n = 65 Type 1 and n = 58 Type 2) (the Italic Point
Estimates are Plotted in Fig. 3)
Outcome: Type 1 and Type 2 MI Outcome: Type 1 MI Outcome: Type 2 MI
HR 95% CI aHR 95% CI aHR 95% CI aHR 95% CI
Prescription of ABC in the past 6 mo
No 1.00 — 1.00 — 1.00 — 1.00 —
Yes 2.66 1.81 to 3.90 1.84 1.17 to 2.91 1.62 1.01 to 2.94 2.11 1.08 to 4.29
Age (yrs)
,40 0.19 0.12 to 0.32 0.31 0.17 to 0.57 0.16 0.05 to 0.43 0.54 0.24 to 1.36
40–49 0.48 0.31 to 0.72 0.57 0.36 to 0.89 0.50 0.27 to 0.90 0.70 0.37 to 1.32
50–59 1.00 — 1.00 — 1.00 — 1.00 —
$60 1.66 0.87 to 3.14 1.01 0.49 to 2.11 1.34 0.50 to 2.94 1.05 0.15 to 2.22
Sex
Male 1.00 — 1.00 — 1.00 — 1.00 —
Female 1.17 0.78 to 1.77 1.43 0.86 to 2.37 1.81 0.82 to 4.09 1.26 0.58 to 2.48
Race and ethnicity
White 1.00 — 1.00 — 1.00 — 1.00 —
Black 1.37 0.94 to 1.77 1.08 0.70 to 1.66 0.53 0.27 to 0.97 2.47 1.25 to 5.88
Hispanic 0.57 0.27 to 2.00 0.76 0.35 to 1.65 0.87 0.34 to 3.40 0.81 0.23 to 4.00
Other/unknown 0.93 0.42 to 1.22 1.03 0.46 to 2.31 0.70 0.20 to 3.12 2.00 0.68 to 14.52
HIV transmission risk
MSM 1.00 — 1.00 — 1.00 — 1.00 —
IDU 1.79 1.08 to 2.97 0.71 0.34 to 1.48 0.47 0.14 to 1.37 1.06 0.28 to 3.72
Heterosexual 1.09 0.71 to 1.67 0.58 0.34 to 1.00 0.52 0.24 to 1.07 0.63 0.28 to 1.41
Other 2.06 1.12 to 3.76 1.40 0.68 to 2.88 1.90 0.79 to 4.66 0.85 0.20 to 5.30
Year of ART initiation
2001–2004 1.65 1.04 to 2.62 1.60 0.97 to 2.63 2.20 1.17 to 4.16 1.05 0.48 to 2.42
2005–2007 1.00 — 1.00 — 1.00 — 1.00 —
2008–2013 1.14 0.71 to 1.84 1.40 0.84 to 2.31 1.19 0.61 to 2.37 1.70 0.89 to 3.89
Cigarette smoking
Never 1.00 — 1.00 — 1.00 — 1.00 —
Ever 1.73 1.07 to 2.80 1.39 0.83 to 2.34 1.69 0.81 to 4.24 1.12 0.55 to 2.36
Hepatitis C infection
No 1.00 — 1.00 — 1.00 — 1.00 —
Yes 1.77 1.20 to 2.62 1.15 0.66 to 2.00 1.51 0.81 to 3.03 0.82 0.29 to 2.12
Hypertension
No 1.00 — 1.00 — 1.00 — 1.00 —
Yes 4.14 2.90 to 5.90 2.39 152 to 3.77 2.45 1.46 to 4.26 2.29 1.14 to 4.54
Diabetes mellitus
No 1.00 — 1.00 — 1.00 — 1.00 —
Yes 3.89 2.35 to 6.43 1.59 0.86 to 2.95 1.15 0.42 to 2.57 2.75 1.12 to 6.29
Renal function
eGFR $60 1.00 — 1.00 — 1.00 — 1.00 —
eGFR ,60 5.74 3.33 to 9.88 1.60 0.81 to 3.16 1.69 0.60 to 4.35 1.71 0.62 to 4.94
High LDL
No 1.00 — 1.00 — 1.00 — 1.00 —
Yes 1.16 0.69 to 1.97 0.83 0.46 to 1.50 0.94 0.45 to 1.83 0.60 0.17 to 3.39
TC:HDL ratio
,5.0 1.00 — 1.00 — 1.00 — 1.00 —
$5.0 1.37 0.89 to 2.10 1.24 0.77 to 2.00 1.49 0.81 to 2.90 0.95 0.46 to 1.99
High triglycerides
No 1.00 — 1.00 — 1.00 — 1.00 —
Yes 1.37 0.89 to 2.10 0.82 0.49 to 1.36 0.82 0.42 to 1.49 0.77 0.33 to 1.46
Statin use
No 1.00 — 1.00 — 1.00 — 1.00 —
MSM analysis, we constructed the necessary stabilized
weights as the product of probabilities from 3 models:
initiating ABC, discontinuing ABC once initiated, and
censoring (see Supplemental Digital Content Fig. 2, http://
links.lww.com/QAI/B120 for box plots of the stabilized
weights). Our primary analysis estimated the relationship
of recent ABC use with the combined T1MI and T2MI
outcome. Two subgroup analyses were performed. First, the
outcome was redefined as T1MI only; individuals who had
a T2MI were excluded altogether from the T1MI analysis.
For the second subgroup analysis, the outcome was redefined
as T2MI; persons with a T1MI were altogether excluded
from the T2MI analysis. Because of the decreased number of
events when stratified by MI type, we used a bootstrapped
approach using the bootstrap-t approach (1000 first iterations
and 25 second iterations) to estimate 95% confidence
intervals for the subgroup analyses.
Two sensitivity analyses were performed. First, to test
the a priori hypothesis that Framingham risk score (FRS)
TABLE 2. (Continued ) Estimated Crude HR and aHR and 95% Confidence Intervals (95% CI) from Marginal Structural Models for
the Risk of MI After ART Initiation, Overall and by MI Type, N = 8265 and n = 123 MIs (n = 65 Type 1 and n = 58 Type 2) (the Italic
Point Estimates are Plotted in Fig. 3)
Outcome: Type 1 and Type 2 MI Outcome: Type 1 MI Outcome: Type 2 MI
HR 95% CI aHR 95% CI aHR 95% CI aHR 95% CI
Yes 3.12 1.89 to 5.15 1.62 0.84 to 3.14 2.17 0.94 to 4.74 0.76 0.19 to 5.13
CD4 count (cells/mm3)
$350 1.00 — 1.00 — 1.00 — 1.00 —
200–349 0.93 0.53 to 1.64 0.97 0.54 to 1.75 0.78 0.40 to 1.74 1.56 0.52 to 4.45
,200 1.89 1.15 to 3.10 1.66 0.97 to 2.81 1.21 3.23 1.28 to 9.14
HIV viral load (copies/mL)
#400 0.92 0.48 to 1.78 0.84 0.42 to 1.66 0.78 0.28 to 2.00 0.76 0.22 to 3.53
.400 1.00 — 1.00 — 1.00 — 1.00 —
History of clinical AIDS diagnosis
No 1.00 — 1.00 — 1.00 — 1.00 —
Yes 2.33 1.62 to 3.34 1.54 1.03 to 2.29 1.06 0.61 to 1.86 2.14 1.30 to 4.11
The T1MI and T2MI models used a bootstrap-t approach to estimate the 95% confidence intervals due to the decrease in power in these subgroups, which approximately divided
the number of events into the 2 groups.
The models were adjusted for all the covariates seen here and cohort (time-fixed).
Prescription of ABC in the past 6 months is time-varying.
Age was a time-varying variable.
Sex, race/ethnicity, and HIV transmission risk group were measured at enrollment into the NA-ACCORD.
Year of ART initiation was a time-fixed variable.
Cigarette smoking status was determined as ever having medical record information or substance survey information that denoted cigarette smoking.
Hepatitis C infection was defined as (1) a positive antibody test, or (2) a detectable HCV RNA, or (3) the presence of a genotype result. If an individual ever met this definition, they
were considered HCV-infected at all times under observation (a time-fixed variable).
Treated hypertension was defined as (1) a hypertension diagnosis, and (2) prescription for an antihypertensive medication. Treated hypertension was measured as close to study
entry as possible, within the window of before study entry through 9 months after study entry and was time-fixed.
Diabetes was defined as (1) a diabetes diagnosis and prescription for diabetes-related medications, or (2) prescription for a diabetes-specific medication, or (3) hemoglobin A1C
$6.5%. Diabetes was measured as close to study entry as possible, within the window of before study entry through 9 months after study entry and was time-fixed.
Renal function was estimated as eGFR calculated using the Chronic Kidney Disease Epidemiology Collaboration study equation. Renal function was measured as close to study
entry as possible, within the window of before study entry through 9 months after study entry and was time-fixed.
High low-density lipoprotein (LDL) was defined as LDL $130 mg/dL. If there was an LDL measurement $130 mg/dL within the window of before study entry through 9 months
after study entry, then the individual was classified as having high LDL for the entire time they were under observation; otherwise, they were classified as having LDL ,130 mg/dL.
High triglycerides was defined as triglycerides $300 mg/dL. If there was a triglyceride measure $ 300 mg/dL within the window of before study entry through 9 months after
study entry, then the individual was classified as having high triglycerides for the entire time they were under observation; otherwise, they were classified as having triglycerides ,300
mg/dL.
Statin use included prescription of cerivastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, pravastatin & aspirin, atorvastatin & amlodipine, ezetimibe &
simvastatin, pitavastatin, lovastatin & niacin. Statin prescription was measured within the window of before study entry through 9 months after study entry.
CD4 count and HIV RNA were measured at measured as close to study entry as possible, within the window of 9 months before study entry through 3 months after study entry.
History of clinical AIDS diagnosis was defined as those who had a first clinical AIDS diagnosis at, or before, study entry.
Bold signifies statistical significance (P , 0.05).
HDL, high-density lipoprotein.
prevalence of other known MI risk factors) receiving ABC 
because of the contraindication for TDF use by such 
persons.31 The use of MSM also accounts for time-
dependent confounding of the ABC and MI relationship 
occurring after ART initiation. Individuals began contrib-
uting person-time to the analysis from the time of ART 
initiation until the earliest date of: (1) incident MI; (2) 
death; (3) 6 months after discontinuation of ABC use 
(because our measure of interest was current or recent ABC 
use, within the previous 6 months); (4) loss to follow-up 
(defined as 1 year after last CD4 or HIV RNA measure-
ment); or (5) administrative censoring at the last date of the 
cohort full MI observation, or December 31, 2013. As 
noted above, participants with a validated MI at, or before, 
study entry were excluded as they were no longer at risk for 
their first MI event.
Individuals who initiated a non–ABC-containing ART 
regimen but subsequently received ABC were included and 
contributed person-time to the appropriate group. For the
FIGURE 2. Cumulative incidence of MI, by Framingham risk score, NA-ACCORD. Numbers below the x-axis denote the number
of participants at risk at 1, 4, and 8 years after ART initiation (top: high risk; middle: intermediate risk; bottom: low risk). MI, T1MI
and T2MI; primary, T1MI; secondary, T2MI.
modified the effect of ABC use on MI occurrence, we used 
a global test of heterogeneity with a nested-models approach 
to determine whether the MSM model with an interaction 
term for ABC and FRS was a better fit, providing statistical 
evidence of interaction. Second, we estimated a naive model 
that did not account for the channeling bias or time-dependent 
confounding by removing the weights. Although all the 
variables in the MSM were retained in the naive model, we 
measured all confounders at study entry; only recent ABC use 
and age were time-varying.
Finally, we replicated the analysis published by the original 
D:A:D report of the relationship of ABC and MI.22 By replicating 
the D:A:D approach, we sought to evaluate whether similar 
findings could be ascertained among these 2 distinct study 
populations using similar methods. See Supplemental Digital 
Content Figure 1, Table 1, and Table 4, http://links.lww.com/
QAI/B120 for details on the D:A:D replication analysis.
All analyses were performed using SAS version 9.3 
(SAS Institute) and a P-value ,0.05 guided 
statistical interpretations.
RESULTS
A total of 8265 adults contributed 29,077 person-years 
and 123 events (65 T1MI and 58 T2MI). Median follow-up time 
was 2.9 (interquartile range 1.4–5.1) years. Median follow-up 
time was similar in ABC initiators [3.0 (interquartile range 1.4–
5.5) years] compared with persons who initiated other ART 
regimens [median = 2.9 (1.5–5.1), P = 0.27]. Compared with
persons who did not initiate ABC, ABC initiators were more 
likely to be older, female, Black, have a history of IDU and 
heterosexual HIV transmission risk, have HCV infection, treated 
hypertension, diabetes, impaired kidney function, elevated total 
cholesterol, elevated triglycerides, low (,200 cells/mm3) CD4  
count, and a history of clinical AIDS diagnosis at study entry 
(Table 1). There was a decrease in ABC use (defined as $1 
month of ABC use) from a peak of 39% of participants in 2002 
to a low of 9% in 2013 (Supplemental Digital Content Fig. 3, 
http://links.lww.com/QAI/B120).
The primary analysis of the combined MI outcome 
showed an increased risk among persons who had used ABC 
in the previous 6 months (P , 0.0001); this difference 
persisted when stratifying the outcome by MI type (T1MI P 
, 0.0001 and T2MI P , 0.0001, Fig. 1). The proportion of 
MI events that were type 1 or type 2 did not vary significantly 
by calendar period.
After accounting for potential channeling biases and 
time-varying confounding in the MSM approach, persons 
with recent ABC exposure had an 84% increase in MI risk 
compared with those without recent ABC exposure [adjusted 
hazard ratio (aHR) = 1.84 (1.17–2.91), Table 2]. Stratifying 
by MI type (T1MI or T2MI),22 there was a 62% increase in 
the risk of T1MI with recent ABC [aHR = 1.62 (1.01–2.94)]; 
the risk of T2MI was 2-fold with recent ABC use [aHR = 
2.11 (1.08–4.29)].
To address the a priori hypothesis that CVD risk 
modified the effect of ABC on MI occurrence, FRSs at study 
entry were estimated for participants. Cumulative incidence
The point estimates for the relationship of ABC and MI
from the main analysis, subgroup analyses, sensitivity
analyses, and the D:A:D replication and original studies can
be visually compared in Figure 3.
DISCUSSION
In this large, demographically diverse cohort of adults
with HIV in care, we identified an increased risk of MI
associated with recent use of ABC (vs. use of ART not
including ABC). This association was apparent regardless of
MI type, both T1MI and T2MI. Although ABC recipients
were enriched for traditional risk factors for T1MI (compared
with non-ABC recipients) including kidney disease, our
methods accounting for channeling biases and time-
dependent confounding adjusted for this potential bias. In
models that included a priori stratification for FRS or specific
adjustment for FRS, we observed no attenuation of the
magnitude of the association between recent ABC use with
MI occurrence.
Furthermore, we were able to evaluate whether
differential associations between ABC use by MI type
FIGURE 3. Estimated risk of MI with recent (within the past 6 months) ABC use under different approach and model scenarios.
The “MSM” is the marginal structural model approach; the main analysis. The “MSM restricted to type 1 MIs” excluded in-
dividuals with a type 2 MI. Ninety-five percent confidence intervals were bootstrapped. The “MSM restricted to type 2 MIs”
excluded individuals with a type 1 MI. Ninety-five percent confidence intervals were bootstrapped. The “MSM adjusted for FRS”
model included both type 1 and type 2 MIs in the outcome as well as participants’ FRS at baseline (intermediate/high vs. low risk).
The “naive analysis” removed the weights from the MSM model. The model estimated the risk of the combined T1MI and T2MI
outcome among those with and without recent ABC exposure, not accounting for potential channeling bias or time-dependent
confounding. The “MSM,” “MSM restricted to type 1 MIs,” “MSM restricted to type 2 MIs,” MSM adjusted for FRS,” and “naive
analysis” models were adjusted for age, sex, race and ethnicity, HIV transmission risk group, year of ART initiation, cigarette
smoking, hepatitis C infection, treated hypertension, diabetes mellitus, renal function, high low-density lipoprotein, total cho-
lesterol:high-density lipoprotein ratio, high triglycerides, statin use, CD4 count, HIV viral load, and a history of clinical AIDS
diagnosis. The “D:A:D replication” estimate was made using the NA-ACCORD data following the D:A:D, JID, 210 approach. This
effect of ABC was adjusted for cumulative exposure to ABC, age, sex, race and ethnicity, HIV transmission risk group, cigarette
smoking, years since ART initiation, calendar year, and cohort. Unlike the D:A:D approach, measures of family history of CVD,
previous CVD, and body mass index were not available or included in the model. The “D:A:D, JID, 2010” point estimate is from
Worm et al, JID, 2010.
of combined MI was highest among persons with the highest 
FRS (Fig. 2). Stratification by MI type demonstrated that the 
ABC use/MI relationship persisted with T1MI, as expected, 
and also with T2MI. There was no statistical evidence that 
FRS modified the effect of ABC on the risk of combined MI 
(P-value of interaction = 0.14). To further adjust for any 
differences by CVD risk, we included FRS in the MSM 
approach after excluding those variables already included in 
the FRS; the effect of recent ABC use on combined MI 
remained similar [aHR = 1.88 (1.20–2.95), Supplemental 
Digital Content Table 2, http://links.lww.com/QAI/B120].
In the analysis restricted to ART naïve persons who 
were observed to initiate ART, channeling biases that may 
have existed among persons with greater risk factors for 
T1MI were not taken into account; in this analysis, there was 
a 75% increase in the risk of combined MI with recent ABC 
use [aHR = 1.76 (1.15–2.68), Supplemental Digital Content 
Table 3, http://links.lww.com/QAI/B120].
The results of the replicated D:A:D approach in the NA-
ACCORD [aHR = 1.63 (1.21–2.18)] were remarkably similar to 
the D:A:D’s findings [aHR = 1.70 (1.17–2.47), Supplemental 
Digital Content Table 4, http://links.lww.com/QAI/B120].
existed. This is particularly relevant because recent work 
from our group has demonstrated that 45% of MIs 
occurring among adults with HIV are T2MI.1 Although 
we found that recent ABC use was associated with MI 
occurrence regardless of type, the magnitude of the 
association may be higher in T2MI. In several studies, 
increased MI risk has been associated with recent ABC use 
(within approximately 6 months of last use), implying that 
the pro-MI effects diminish within 6 months of ABC 
discontinuation. Our study purposely focused on recent and 
early (part of first ART regimen received) ABC exposure, 
with the advantage of using adjudicated MIs, a design that 
mimicked a clinical trial of ART initiation and included 
both T1MI and T2MI. However, some studies have also 
suggested that cumulative exposure to ABC beyond 6 
months may further increase MI risk,32,33 possibly out to 
24–36 months of exposure. Precise mechanisms by which 
ABC exposure increases the risk of MI are not currently 
clear. Our current understanding of potential pathophysi-
ologic mechanisms by which ABC use may contribute to 
MI risk include promotion of enhanced platelet activation, 
aggregation, and increased adhesion to vascular endothelial 
cells (and consequent promotion of thrombus formation) 
through interference with processing of purinergic media-
tors, resulting in an overall ABC effect that seems to 
involve endothelial activation.34 Although prothrombotic 
states probably exist for both T1MI and T2MI, ABC’s 
effect feasibly could create an enhanced vulnerability to MI 
that is distinct from, but possibly additive to, MI risk from 
preexisting coronary atherosclerosis or systemic inflamma-
tion or immune dysregulation. Such an effect could 
manifest early during ABC exposure but feasibly could 
also be an ongoing effect that is cumulative in nature.
Although exact mechanism(s) by which ABC exerts 
pro-MI effects remain speculative, our results suggest that 
clinical screening practices for MI risk among adults with 
HIV focused only on more traditional T1MI risks may be 
insufficient. As many as 50% of the T2MIs in NA-ACCORD 
are related to sepsis, cocaine use, or “other illicit drug-
induced vasospasm,26,31 and in the current analysis, we found 
an adjusted HR of 1.76 among IDU for T2MI. Such findings 
are consistent with observations from the French Hospital 
Database on HIV, which reported that, after adjustment for 
cocaine or recreational intravenous drug use, an association 
between recent ABC use and MI was not apparent.18 In 
addition, recent work35 demonstrated a prominent association 
of cocaine use with the development of MIs among adults 
with HIV, prompting the suggestion that treating cocaine 
addiction may comprise an important adjunctive measure in 
MI prevention for this patient group.
Our analysis identified other risk factors for T2MI, 
including Black race, hypertension, and diabetes, tradi-
tional risk factors for T1MI, as well as a CD4 ,200 cells/
mm3. It is important to note that our analysis was not 
focused on describing the mechanism of any ART-related 
causations of MI, but rather isolating the effect of recent 
ABC use on MI risk in the context of channeling bias and 
time-dependent confounding. After adjusting for other 
factors in the model, these variables continued to be
independently associated with T2MI. The identification of 
the prominence of T2MIs among persons living with HIV, 
as  described by Drozd et al1, and our current finding of an 
independent association between recent ABC use and MI 
(both T2MI and T1MI) broaden our understanding of the 
spectrum of potential etiologies of MIs in this population. 
Potential interactions between lifestyle-related factors, 
genetics, inflammation, various causes of hypoxemia, and 
exposures to specific ARV drugs may help to expand our 
understanding of the diverse etiologic factors contributing 
to MI among persons living with HIV.
The NA-ACCORD differs from randomized inter-
ventional ART trials from which some ABC and MI data 
have been analyzed previously (such as those included in 
the Food and Drug Administration meta-analysis)20 
because the NA-ACCORD analysis reflects data involving 
ABC utilization in clinical practice, including among adults 
at diverse stages of HIV disease with various types of MI 
risk factor profiles, and involved much longer follow-up. 
Our present study also represents an important improve-
ment in verification of clinical MI events, Including 
designation into T1MI or T2MI categories. No MIs were 
included that were based only on participant self-report or 
on clinical International Classification of Diseases codes 
alone. Uniquely, there were a sufficient number of adults 
with available data from the time of ART initiation while 
observed in the NA-ACCORD, analysis of whom not only 
avoided potential analytic biases associated with prevalent 
ART use36 but also enabled the use of MSM approaches 
that seek to overcome analytic challenges involving time-
dependent confounding. The D:A:D investigators were 
conscientious of excluding potential mediators from the 
analysis,22but in doing so, questions were raised as to 
whether the findings would be corroborated with alterna-
tive approaches. We note that an earlier analysis from the 
NA-ACCORD showed a weaker, although qualitatively 
similar, adjusted association between ABC exposure and 
MI.37 Unlike the previous analysis, the current analysis 
limited the study sample to patients who were observed to 
initiate ART to better mimic a clinical trial. We were also 
able to add more recently adjudicated MIs to the sample, 
although the selection criteria necessary for the our 
approach restricted the sample and associated number of 
MI events in comparison with another previous NA-
ACCORD study (Supplemental Digital Content Fig. 1, 
http://links.lww.com/QAI/B120).1
We acknowledge that as an observational study lacking 
a randomized assignment of ABC, confounding is still possible 
and many variables exist that could potentially be predictive not 
only of MI occurrence but also of the prescribing of ABC. Our 
methods adjusted for kidney function, which is associated with 
ABC and TDF prescription, and also for T1MI risk factors such 
as diabetes, proatherogenic hyperlipidemia, hypertension, and 
smoking, which may also impact the prescribing of ABC. To 
date, we are not aware of evidence that risk factors for T2MI 
(sepsis, cardiac arrhythmia, recreational drug use, anemia, an 
impaired functional level, and female sex) are associated with 
ABC and TDF prescribing and there is no apparent reason to 
suspect that ABC recipients would be enriched in T2MI risks
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